Pharmaceutical Companies
[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]
Sponsored Ads
|
| Get all news digests delivered to your inbox, subscribe to World Pharma News Google Group.
|
World Pharma News .net / Published News
Sponsored Ads
|
|
Amgen News Service: Press Releases
|
|
-
Amgen Positioned to Deliver Attractive Growth Over Next Five Years
NEW YORK – Nov 07, 2008 – At an Amgen (Nasdaq: AMGN) meeting of about 200 securities analysts and investors in New York City today, several members of its senior management team outlined the Company?s growth strategy, which includes delivering on its pipeline?including the experimental bone drug denosumab?growing in-line products and continuing to pursue operating efficiencies.
"In 2001, Amgen had two blockbuster products and today we have five blockbusters on the market," said Amgen Chairman and CEO Kevin Sharer. "Over the next five years we could have three more drugs achieve blockbuster status: Sensipar(R) (cinacalcet), denosumab for osteoporosis and denosumab for cancer-related indications."
-
Call for Applications: The Amgen Award for Science Teaching Excellence
THOUSAND OAKS, Calif. – Nov. 3 – Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 18th annual Amgen Award for Science Teaching Excellence (AASTE). This award is designed to recognize and honor extraordinary science teachers at the K-12 level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student learning in communities where Amgen operates.
-
Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
SAN FRANCISCO – Oct. 27 – Amgen (Nasdaq: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that ENBREL is the first biologic with published clinical trial data to show sustained improvements in multiple measures of efficacy in moderate to severe rheumatoid arthritis (RA) patients completing up to 10 years of therapy. In this analysis, the safety profile remained consistent with continuous ENBREL use for up to 10 years. These new data are being presented at the American College of Rheumatology (ACR) Scientific Meeting in San Francisco. (Abstract 1007; Poster Board 268)
-
Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
Third Quarter 2008 Revenue Increased 7 Percent to $3.9 Billion
Third Quarter 2008 GAAP Earnings Per Share were $1.09, an Increase from Third Quarter 2007 GAAP Earnings Per Share of $0.18
Full Year Revenue Guidance Raised from $14.6 Billion - $14.9 Billion to $14.9 Billion - $15.2 Billion
Full Year Adjusted EPS Guidance Raised from $4.25 - $4.45 to $4.45 - $4.55
THOUSAND OAKS, Calif., Oct. 22 – Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.23 for the third quarter of 2008, an increase of 14 percent compared to $1.08 for the third quarter of 2007. Adjusted net income, excluding stock option expense and certain other expenses, increased 11 percent to $1,308 million in the third quarter of 2008 compared to $1,181 million in the third quarter of 2007. Stock option expense on a per share basis totaled 2 cents for both the third quarter of 2008 and the third quarter of 2007.
-
Amgen Issues Statement on Court of Appeals Ruling That Affirms Preliminary Injunction Against Roche
THOUSAND OAKS, Calif. – Today the United States (U.S.) Court of Appeals for the Federal Circuit issued a ruling that affirms the preliminary injunction ordered by the U.S. District Court in Boston barring Roche from selling its pegylated-erythropoietin (peg-EPO) product MIRCERA in the U.S.
-
Amgen Appoints Francois de Carbonnel to the Company's Board of Directors
THOUSAND OAKS, Calif. – Oct 03, 2008 – Amgen (NASDAQ:AMGN) announced today that its Board of Directors has appointed Francois de Carbonnel to the Company?s Board. Mr. de Carbonnel, 61, is a consultant and corporate financial advisor. He is also chairman of the board of Thomson S.A. (Euronext Paris:18453; NYSE:TMS), an international multimedia corporation. He is also a member of the boards of Pages Jaunes S.A., a French public company, Quilvest S.A., a public Luxembourg company, Ecofin Global Utilities Hedge Fund Ltd. and Ecofin North America Utilities Hedge Fund Ltd., both Irish public companies. His appointment brings the number of Amgen Board members to 12. Mr. de Carbonnel will serve as a member of the Audit and Governance and Nominating Committees of the Board.
-
District Court Affirms Patent Infringement Rulings and Finds That Amgen is Entitled to a Permanent Injunction against Roche
THOUSAND OAKS, Calif. – Amgen (NASDAQ:AMGN) announced today that the United States (U.S.) District Court in Boston issued its written decision upholding the prior jury verdict and court rulings regarding the infringement, validity and enforceability of 10 claims of four of Amgen?s erythropoietin (EPO) patents. The Court also ruled that Amgen is entitled to a permanent injunction prohibiting Roche from selling its pegylated-erythropoietin (peg-EPO) product MIRCERA in the U.S. Previously, the Court entered a preliminary injunction preventing Roche from selling peg-EPO, and Roche has appealed that ruling. In today?s decision, the District Court stated that it would enter a permanent injunction once the appeal of the preliminary injunction is resolved.
-
Amgen Receives Executive Summary from Independent Cochrane Collaboration Review of ESAs in Oncology
THOUSAND OAKS, Calif., – Sep 30, 2008 – Amgen Inc., (NASDAQ: AMGN) announced it has received a summary of preliminary results from the Cochrane Collaboration?s independent meta-analysis of patient-level data from previously conducted, randomized, controlled, clinical studies evaluating erythropoiesis-stimulating agents (ESAs) in cancer patients. Amgen has submitted the executive summary to regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA).
-
Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate
Additional Data From Separate Head-to-Head Trial Showed More Than 75 Percent of Patients Prefer the Administration and Frequency of Twice-Yearly Subcutaneous Injection Compared to Weekly Oral Pill
MONTREAL – Sept. 15, 2008 – Amgen (NASDAQ:AMGN) today announced full data results from a non-pivotal Phase 3 head-to-head, double-blind trial comparing bone mineral density (BMD) gains in postmenopausal women with low bone mass who transitioned from weekly oral alendronate (Fosamax(R)) to denosumab versus those who continued alendronate therapy. In addition, patient preference data from another non-pivotal head-to-head trial comparing denosumab to weekly oral alendronate were announced today at the 2008 American Society of Bone and Mineral Research (ASBMR) Annual Meeting in Montreal.
-
Biovitrum to Acquire Kepivance(R) and Stemgen(R) and Exclusively License Kineret(R) from Amgen
STOCKHOLM, Sweden & THOUSAND OAKS, Calif. – Sept. 15, 2008 – Biovitrum AB (publ) (STO:BVT) and Amgen (NASDAQ:AMGN) announced today that they have entered into an agreement under which Biovitrum will acquire the marketed biologic therapeutic products Kepivance(R) (palifermin) and Stemgen(R) (ancestim) from Amgen, and will also obtain from Amgen a worldwide exclusive license to Kineret(R) (anakinra) for its current approved indication. The agreement includes an inventory of the three products at an undisclosed value.
|
|
|
news
European Commission - Pharmaceuticals
US Food and Drug Administration 
